

Patient: [REDACTED]  
 DOB: [REDACTED] Age: [REDACTED] Gender: [REDACTED]  
 Patient Identifiers: [REDACTED]  
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]  
 Physician: [REDACTED]


ARUP Test Code: 2013605  
 Collection Date: 12/16/2016  
 Received in lab: 12/17/2016  
 Completion Date: 12/19/2016

**Patient History \***

<u>Collection Date</u>	<u>Adalimumab Activity (ADA) ug/mL</u>	<u>Accession Number</u>
12/16/2016	9.30	16-351-402955

**Adalimumab Activity**

—●— ADA



Cutoff values are 0.65 ug/mL for adalimumab and 1:20 for antidrug antibody (NAb).

\*Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information on this chart appears incomplete, please consult this patient's prior charts.



Patient: [REDACTED]  
 ARUP Accession: 16-351-402955

# Adalimumab Activity with Reflex to Antibody

Patient: [REDACTED] | Date of Birth: [REDACTED] | Gender: [REDACTED] | Physician: [REDACTED]  
Patient Identifiers: [REDACTED], [REDACTED] | Visit Number (FIN): [REDACTED]

## Interpretive Comments

**Interpretive Data:** This test measures the capacity of adalimumab to neutralize TNF-alpha activity. Additionally, adalimumab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).

This test is used to evaluate secondary response failures to adalimumab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating adalimumab levels have been shown to vary considerably between patients. These differences relate to route and requery of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant dications such as methotrexate and other immunosuppressants.

IF Adalimumab Activity is...	AND Adalimumab Neutralizing Antibody Titer is...	THEN...
Not Detected	Not Detected	A higher dosage of adalimumab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Detected	A change to another type of therapy (not targeting TNF-alpha) may be appropriate.

METHODOLOGIES USED: Cell Culture, Cell function assay involving cell stimulation, Quantitative Chemiluminescent Immunoassay, Semi-Quantitative Chemiluminescent Immunoassay

See Compliance Statement B: [www.aruplab.com/CS](http://www.aruplab.com/CS)



Patient: [REDACTED]  
ARUP Accession: 16-351-402955